MOTHAFFAR RIMAWI to Survival Rate
This is a "connection" page, showing publications MOTHAFFAR RIMAWI has written about Survival Rate.
Connection Strength
0.046
-
TBCRC 022: A Phase II Trial of Neratinib and Capecitabine for Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases. J Clin Oncol. 2019 05 01; 37(13):1081-1089.
Score: 0.027
-
Chemotherapy for isolated locoregional recurrence of breast cancer (CALOR): a randomised trial. Lancet Oncol. 2014 Feb; 15(2):156-63.
Score: 0.019